The regulatory milestone positions the Danish drugmaker to capture a larger share of a rapidly expanding sector as global manufacturers race to offer pill-based alternatives to injectable treatments.
Market Dynamics and Obesity Projections in China
Rising obesity rates across China are driving significant commercial growth in the GLP-1 therapeutic class. This demographic shift has turned the domestic pharmaceutical market into a primary battleground for international drug developers.
Competitive Landscape: Novo Nordisk Versus Eli Lilly
Novo Nordisk’s application for oral Wegovy follows a similar move by rival Eli Lilly, which submitted a marketing application for its once-daily oral candidate, orforglipron, to Chinese regulators in March, according to Investing.com. Both companies are working to attract patients who prefer daily oral medications over weekly or daily injections. Additional market competitors in the broader Chinese GLP-1 space include Pfizer and domestic firm Innovent Biologics, as reported by Investing.com.
Economic Impact and Sales Projections
Market analysts project substantial economic expansion for the sector over the next decade. According to estimates cited by Investing.com, total sales for GLP-1 weight-management therapies in China are expected to surge from a current range of 3 billion to 4 billion yuan up to 30 billion yuan—approximately $4.46 billion USD—within the next five to seven years. The entry of oral alternatives is expected to accelerate product adoption and reshape market leadership across the region.